PubMed

Regulatory science for AI-based software as a medical device in computational pathology and biomarker-driven drug development.

PMID: 42436740 · 2026-06-11

Y, a, e, l, , L, i, e, b, e, s, -, P, e, e, r, ;, , S, h, l, o, m, o, , C, z, e, i, s, l, e, r, ;, , R, a, c, h, e, l, , B, r, o, d, e, r, i, c, k, ;, , M, a, n, u, e, l, a, , V, e, c, s, l, e, r, ;, , Y, a, i, r, , H, e, l, l, e, r, ;, , C, h, a, i, m, , L, i, n, h, a, r, t, ;, , J, o, s, e, p, h, , M, o, s, s, e, l, ;, , J, o, c, h, e, n, , K, , L, e, n, n, e, r, z

ЖурналJournal of pathology informatics

Год2026-06-11

PMID42436740

Аннотация

Artificial intelligence (AI)-enabled software is increasingly integrated into digital and computational pathology, driving new regulatory and quality management requirements that extend beyond traditional laboratory practice and classical medical-device oversight. Practical, experience-based guidance on balancing development agility with global regulatory readiness remains limited for biomarker developers and translational pathologists navigating the convergence of AI governance, cybersecurity,

Официальный источник

Открыть в PubMed →

Данные получены из PubMed / NCBI. Полный текст и наиболее актуальную информацию всегда смотрите в официальной записи.